

6 **Urban parks biowaste as a sustainable source of new**
7 **antidiabetics**

9 MARIJAN MARIJAN¹ ORCID^s. 0000-0002-1095-0902

10 LEJSA JAKUPOVIĆ¹ ORCID 0000-0002-1714-6706

11 LOVORKA VUJIĆ² ORCID0000-0002-8755-9960

12 MARINA JURIC¹ ORCID 0009-0005-2089-2573

13 MARIJANA ZOVKO KONČIĆ^{1,*} ORCID 0000-0002-
14 8787-6667

16 ¹ *University of Zagreb Faculty of Pharmacy and Biochemistry,*
17 *Department of Pharmacognosy, 10000 Zagreb, Croatia*

18 ² *University of Zagreb Faculty of Pharmacy and Biochemistry,*
19 *Department of Nutrition and Dietetics, 10000 Zagreb, Croatia*

21 **ABSTRACT**

22 Biowaste produced in urban parks is composed of large
23 masses of organic matter that is only occasionally used
24 economically. In this work, extracts of six plants widely
25 distributed in urban parks in Central Europe (*Achillea*
26 *millefolium*, *Cichorium intybus*, *Malva sylvestris*, *Medicago*
27 *sativa*, *Plantago lanceolata*, and *Trifolium pratense*), prepared
28 using 10 % and 50 % ethanol, were screened for their
29 antidiabetic and related properties. HPLC and UV-VIS analysis
30 revealed presence of caffeic acid, quercetin, luteolin, and
31 apigenin derivatives. The extracts were active in DPPH
32 antiradical, β -carotene-linoleic acid, ORAC, and reducing power
33 assay. They inhibited lipoxygenase, collagenase, as well as heat-

34 induced ovalbumin coagulation. They were also able to hinder
35 carbohydrate degradation. For example, IC_{50} of anti- α -amylase
36 activity of 10 % and 50 % ethanol extract of *M. sativa* extracts
37 ($204.10 \pm 2.11 \mu\text{g mL}^{-1}$ and $78.27 \pm 0.99 \mu\text{g mL}^{-1}$, respectively)
38 did not statistically differ from the activity of the positive
39 control, acarbose ($284.74 \pm 3.81 \mu\text{g mL}^{-1}$). Similar results were
40 observed for their anti- α -glucosidase activity. In most assays,
41 use of 50 % ethanol was shown to be better suited for extraction
42 of active metabolites. The results indicate that the biowaste
43 obtained from urban parks represents a potential source of plant
44 material for the preparation of high-value antidiabetic products.

45 *Keywords:* antidiabetic, antihyperglycemic, anti-
46 inflammatory, HPLC, natural phenols, waste management

47

48 * Correspondence; e-mail: marijana.zovko@pharma.unizg.hr

49

50 Accepted November 18, 2024

51 Published online November 19, 2024

52

53

54 INTRODUCTION

55 Type 2 diabetes (T2D) is a condition frequently associated
56 with poor dietary habits and a lack of physical activity. It is
57 estimated that T2D impacts over 30–40 % of individuals aged 65
58 and older (1). This disorder is characterized by insulin resistance
59 that leads to elevated blood sugar levels, inflammation (2), and
60 overproduction of reactive oxygen species (ROS), resulting in a
61 persistent state of oxidative stress (3). Despite advancements in
62 treatment strategies for T2D, antidiabetic medications may have
63 serious shortcomings, including the risks of hypoglycemic
64 episodes and complications affecting the liver and kidneys. The
65 use of medicinal plants or plant-based therapies is considered to

66 be a cost-effective approach used globally for the prevention,
67 amelioration of consequences, and, to some extent, even therapy
68 of T2D. Numerous studies suggest that medicinal plants can
69 influence carbohydrate and lipid metabolism, reduce
70 hyperglycemia, dyslipidemia, and insulin resistance, as well as
71 mitigate oxidative stress and inflammatory responses (4, 5).
72 Medicinal plants contain various secondary metabolites that
73 exhibit antidiabetic properties, and many contemporary
74 pharmaceuticals are derived from phytoconstituents of
75 traditional medicinal flora. For instance, the biguanide
76 antihyperglycemic medication metformin has its origins in the
77 traditional use of *Galega officinalis* L. for diabetes treatment (6).
78 For all this reasons, the World Health Organization (WHO)
79 endorses the incorporation of medicinal plants into dietary
80 practices for the managing of T2D (6).

81 Among secondary metabolites that influence biological
82 targets and provide therapeutic benefits in the management of
83 T2D, polyphenols occupy a special place. They demonstrate
84 their antidiabetic effects *via* multiple mechanisms, such as
85 antioxidant activity and inhibition of digestive enzymes (7).
86 Numerous studies have shown that the use of complex mixtures
87 of phenolics and other plant metabolites, such as those present in
88 plant extracts, could result in synergistic action of active
89 principles and, consequently in their increased efficiency (8).
90 However, due to their unique chemical characteristics,
91 phytochemicals may display different solubilities in different
92 solvents. Consequently, the choice of solvent can strongly affect
93 the composition and, as a result, biological activity of the
94 prepared extracts (9).

95 Urban green spaces, particularly urban parks, constitute a
96 vital element of contemporary cities. These areas are
97 characterized by well-maintained vegetation and serve as crucial
98 reservoirs of biodiversity within urban environments. Their
99 landscape, primarily consisting of grasslands interspersed with

100 occasional trees, bears a strong resemblance to savanna-type
101 ecosystems (10). The biowaste generated in these parks arises as
102 a consequence of the natural growth of plants whose
103 maintenance produce substantial amounts of organic material
104 (11). Despite the significant volume of this biomass, its
105 economic utilization is rather limited, primarily restricted to
106 composting, production or energy generation in biogas facilities
107 or incinerators (12). However, a significant portion of the plants
108 growing in such areas comprise medicinal and edible plants.
109 Therefore, there is a possibility to use this biowaste for the
110 creation of high-value products, including dietary supplements
111 (11), thus lowering the production costs and enhancing its
112 sustainability. A recent study have shown that plants from urban
113 parks may serve as a valuable source of bioactive phenolics
114 suitable for cosmetic applications (13). However, there is still a
115 notable deficiency in research regarding the application of
116 biowaste from urban green spaces in various industrial sectors.

117 Having in mind abundance of medicinal plants in urban
118 parks biowaste, this work aimed to investigate if this resource
119 can be used for production of high-value antidiabetic products.
120 Six plant species identified as common biowaste in urban parks
121 with potential anti T2D activity, *Achillea millefolium* L.,
122 *Cichorium intybus* L. (Asteraceae), *Medicago sativa* L.,
123 *Trifolium pratense* L. (Fabaceae), *Malva sylvestris* L.
124 (Malvaceae), and *Plantago lanceolata* L. (Plantaginaceae) were
125 selected for the study. Their phenolic profiles, antioxidant
126 properties, anti-inflammatory, and antihyperglycemic activities
127 were evaluated and compared. To encompass a broader range of
128 metabolites and identify the most suitable solvent for the
129 potential development of medicines and food supplements
130 derived from these plants, extractions were conducted using two
131 solvents with differing polarities: 10 % and 50 % ethanol (V/V).

132
133

EXPERIMENTAL

134 *Plant materials and chemicals*

135 Flowering aerial parts of selected plants (*A. millefolium*, *C.*
136 *intybus*, *M. sylvestris*, *M. sativa*, *P. lanceolata*, and *T. pratense*)
137 were collected in the recreational area in the city of Zagreb (lake
138 Jarun, 45°48'N 15°90'E) in June 2019. The identity was
139 confirmed by the authors. Standards for HPLC and
140 spectrophotometric determinations were purchased from Sigma-
141 Aldrich (USA). Soybean lipoxygenase (LOX) was a product
142 from TCI chemicals (Japan), while the other enzymes were
143 purchased from Sigma-Aldrich. The purity of all the standards
144 was $\geq 98.5\%$. Other reagents and chemicals were of analytical
145 grade. Extraction was performed using Bandelin SONOREX®
146 Digital 10 P DK 156 BP ultrasonic bath (Germany). Agilent
147 1200 series HPLC instrument equipped with an autosampler,
148 DAD detector, and a Zorbax Eclipse XDB-C18 (5 μm , 250 mm
149 \times 4.6 mm) column and guard column (Agilent Technologies,
150 USA) was used for the determination of the selected secondary
151 metabolites. A microplate reader (FLUOstar Omega, BMG
152 Labtech, Germany) was used for UV-VIS spectroscopic
153 measurements.

154

155 *Preparation of the extracts*

156 Prior to the extraction, plant material was grinded and
157 passed through a sieve of 850 μm mesh size. Thereafter, to the 3
158 g of powdered plant material placed in a 100 mL Erlenmeyer
159 flask, 30 mL of the appropriate solvent (10 % or 50 % ethanol)
160 was added. The flask was then placed in the ultrasonication bath.
161 The extraction was performed at 25 °C for 20 min at 72 W
162 power. Upon the extraction, the mixture was filtered, and the
163 remaining material at filter paper was washed 2 times with 30
164 mL of the same solvent. The extracts were combined in a round-
165 bottom flasks and evaporated under reduced pressure. After
166 drying in a desiccator for 24 h over anhydrous silica gel, dry

167 extracts were stored at +4 °C in the dark until use. The extracts'
168 names were composed using two parts, first being the
169 abbreviation of the plant's name: *A. millefolium* (AM), *C.*
170 *intybus* (CI), *Malva sylvestris* (MSy), *Medicago sativa* (MS), *P.*
171 *lanceolata* (PL), and *T. pratense* (TPr), followed by the second
172 part consisting of the number (10 or 50) representing the
173 percentage of ethanol used for the extraction (*e.g.* MSy10).

174

175 *Spectrophotometric determination of phenolic compounds*

176 Total phenols (TP), content was determined using Folin-
177 Ciocalteau reagent (14), while determination of total flavonoids
178 (TF) was performed in reaction with aluminum chloride (15).
179 Total hydroxycinnamic acids (TCA) content was determined
180 using the reaction with Arnou's reagent (16). Content of TP and
181 TCA was expressed as µg of caffeic acid equivalents (CAE),
182 while the content of TF was expressed as quercetin equivalents
183 (QE) in g of dry mass (DM) of the extract.

184

185 *HPLC analysis of phenolic constituents*

186 Methanolic solutions of the extracts (2 mg mL⁻¹) and the
187 phenolic standards (0.2 mg mL⁻¹ in methanol) were filtered
188 through a 0.45 µm PTFE syringe filter, and subjected to HPLC
189 chromatographic separation at a temperature of 40 °C and flow
190 of 1.2 mL min⁻¹. The solvents A and B were 2 % formic acid
191 (V/V) and acetonitrile applied as follows 0–23 min 0–20 % B,
192 23–27 min 20–22.5 % B, 27–28 min 22.5–24.4 % B, 28–30 min
193 24.4–26.2 % B, 30–50 min 26.2–30 % B, 50–60 min 30–100 %
194 B, 60–61 min 100–0 % B, 61–66 min 0 % B. To construct a
195 calibration curve, varying volumes of standard solutions were
196 injected using an autosampler. The peak assignment and
197 identification was based on comparison of retention times of
198 peaks in sample chromatogram and UV spectra (200–500 nm)
199 with those of the standards. Caffeic acid (CA) and its derivatives,

200 chlorogenic acid (ChA), neochlorogenic acid (NcA), rosmarinic
201 acid (RA), and verbascoside (V) were used as standards for
202 hydroxycinnamic derivatives. Furthermore, apigenin (A),
203 luteolin (L), and quercetin dihydrate (Q), as well as their
204 derivatives apigenin-7-*O*-glucoside (A7G), luteolin-7-*O*-
205 glucoside (L7G), hyperosid (H), isoquercetin (IQ), and
206 quercitrin dihydrate (Qcit) were used flavonoid standards.
207 Calibration curve parameters are reported in Table I.

208

209 *Free radical scavenging activity*

210 Radical scavenging activity (RSA) was evaluated (17) using
211 2,2-diphenyl-1-picrylhydrazyl (DPPH) free radical. Solution of
212 DPPH (70 μL , 0.21 mg mL^{-1} in methanol) was added to 130 μL
213 of extract solution (sample). After 30 min the absorbance was
214 read at 545 nm. RSA was calculated according to the Equation
215 1:

$$\text{RSA (\%)} = \frac{A_{\text{control}} - A_{\text{sample}}}{A_{\text{control}}} \times 100, \quad (1)$$

216 where A_{control} is the absorbance of the negative control
217 (solution that contains methanol instead of extract) and A_{sample} is
218 the absorbance of the DPPH solution containing extract.
219 Butylated hydroxyanisole (BHA) was used as the standard
220 radical scavenger.

221

222 *Antioxidant activity in β -carotene-linoleic acid assay*

223 Antioxidant activity in β -carotene-linoleic acid assay
224 (ACLA) was evaluated using modified literature procedure (18).
225 Emulsion (200 μL) containing β -carotene (6.7 $\mu\text{g mL}^{-1}$), linoleic
226 acid (0.7 mg mL^{-1}), and Tween 40 (6.7 mg mL^{-1}) was added
227 either to water (50 μL) (control) or to the solutions of the extracts
228 in methanol (50 μL). The reaction mixtures were subjected to
229 incubation at 50 $^{\circ}\text{C}$. ACLA was calculated based on the
230 absorbance 459 nm recorded each 5 min for 60 min using the
231 Equation 2:

$$ACLA (\%) = \frac{R_{\text{control}} - R_{\text{sample}}}{R_{\text{control}}} \times 100, \quad (2)$$

232 where R_{control} and R_{sample} are the average reaction rates of β -
233 carotene bleaching for the water control and the antioxidant,
234 respectively, calculated according to the pseudo-first order
235 kinetics. BHA was used as the standard antioxidant.

236

237 *Reducing power assay*

238 The reducing power of extracts (RP) was determined according
239 to the previously used method (19) modified for microtiter
240 plate. The extract solution (80 μL), phosphate buffer (0.2 mol
241 L^{-1} , pH = 6.6, 100 μL), and potassium ferricyanide (1 % m/V ,
242 100 μL) were incubated for 20 min at 50 $^{\circ}\text{C}$. Thereupon,
243 trichloroacetic acid (10 % m/V , 100 μL) was added. An aliquot
244 of 125 μL was transferred to a new plate. After two-fold serial
245 dilution ferric chloride (25 μL , 0.1 %) solution was added. The
246 absorbance was read spectrophotometrically at 700 nm.
247 Ascorbic acid was used as the positive control.

248

249 *Oxygen radical absorbance capacity*

250 For the oxygen radical absorbance capacity (ORAC) assay (20),
251 25 μL of the extract solution or phosphate buffer (75 mmol L^{-1} ,
252 pH 7.4) (blank), and 150 μL of fluorescein (1 $\mu\text{mol L}^{-1}$) were
253 preincubated 37 $^{\circ}\text{C}$. After 10 min, 25 μL of 125 mmol L^{-1} 2,2'-
254 azobis(2-amidinopropane) dihydrochloride (AAPH) was added
255 and the fluorescence was measured kinetically at 37 $^{\circ}\text{C}$ every
256 150 seconds for 60 min. The excitation and emission
257 wavelengths were 485 nm and 528 nm, respectively. The ORAC
258 activity of a sample was calculated by subtracting the area under
259 the blank curve from the area under the sample curve to obtain
260 the net area under the curve. Using Trolox of known
261 concentration, a standard curve was generated and the ORAC
262 activity of the samples was calculated as Trolox equivalents.

263

264 *Table I. Calibration curve parameters for selected phenolic standards*

Phenolic standard	λ (nm)	Equation	R^2	LOD (μg)	LOQ (μg)
Apigenin	365	$y = 1545.95x + 4.48$	0.9999	0.002	0.006
Apigenin-7- <i>O</i> -glucoside	365	$y = 4708.27x + 184.78$	0.9998	0.084	0.279
Caffeic acid	320	$y = 4004.80x + 28.93$	0.9999	0.016	0.053
Chlorogenic acid	320	$y = 2020.89x - 17.88$	0.9999	0.033	0.110
Hyperoside	365	$y = 1567.21x + 9.76$	0.9999	0.007	0.024
Isoquercetin	365	$y = 1286.94x + 14.32$	0.9999	0.004	0.014
Luteolin	365	$y = 2504.96x + 9.67$	0.9999	0.004	0.014
Luteolin-7- <i>O</i> -glucoside	365	$y = 1333.63x + 9.73$	0.9999	0.008	0.028
Neochlorogenic acid	320	$y = 1379.16x + 35.41$	0.9999	0.021	0.070
Quercetin dihydrate	365	$y = 1872.38x - 1.96$	0.9999	0.002	0.006
Quercitrin dihydrate	365	$y = 1055.99x + 4.60$	0.9999	0.018	0.058
Rosmarinic acid	320	$y = 1945.38x + 16.34$	0.9999	0.007	0.025
Verbascoside	320	$y = 346.84x + 8.98$	0.9999	0.037	0.123

265 LOD – level of detection, LOQ – level of quantification, y – area under curve (mAU \times s), x – amount of the standard (μ g).

Uncorrected proof

266

267 *Lipoxygenase inhibitory activity*

268 For determination of lipoxygenase inhibitory activity
269 (LOXI) (21), 50 μL of the extract solution was mixed with 150
270 μL phosphate buffer (pH 8, 100 $\mu\text{mol L}^{-1}$) and 20 μL of soybean
271 LOX solution (1 mg mL^{-1}). Thereupon, linoleic acid (30 μL) was
272 added and the mixture incubated at 25 $^{\circ}\text{C}$. After 10 min the
273 absorbance was determined at 234 nm. The activity was
274 calculated as described in Equation 3:

$$LOX (\%) = \frac{A_{\text{control}} - A_{\text{sample}}}{A_{\text{control}}} \times 100, \quad (3)$$

275 where A_{control} is the absorbance of the negative control
276 (reaction mixture prepared with water instead of the extract) and
277 A_{sample} is the absorbance of the respective extract.
278 Nordihydroguaiaretic acid (NDGA) was used as positive
279 control.

280

281 *Ovalbumin coagulation assay*

282 Heat-induced ovalbumin coagulation assay (OVA) (22) was
283 used for determination of anti-inflammatory activity. Ovalbumin
284 solution (0.4 mL of 50 % fresh hen's albumen) was mixed with
285 phosphate buffered saline (2.8 mL, pH 6.4) and the extract
286 solutions (2 mL). The mixtures were first incubated at 37 $^{\circ}\text{C}$ for
287 15 min and then heated at 70 $^{\circ}\text{C}$ for 5 min. After an additional
288 10 min at room temperature, their absorbance was recorded at
289 660 nm. OVA was calculated using the Equation 4:

$$OVA (\%) = \frac{A_{\text{control}} - A_{\text{sample}}}{A_{\text{control}}} \times 100, \quad (4)$$

290 where A_{control} is the absorbance of the negative control
291 (reaction mixture prepared with water instead of the extract) and
292 A_{sample} is the absorbance of the respective extract. Diclofenac
293 sodium was used as the standard coagulation inhibitor.

294

295 *Collagenase inhibitory activity*

296 Collagenase inhibitory activity assay (COLL) was
297 performed according to Zhanga *et al.* (23) with some
298 modifications. To 40 μL of the extract solution in Tris-HCl
299 buffer (0.1 mol L^{-1} , pH 7.5, 5 mmol L^{-1} CaCl_2 , and $1 \mu\text{mol L}^{-1}$
300 ZnCl_2), 20 μL of collagenase dissolved in the same buffer (1 mg
301 mL^{-1}) was added. After 5 min at room temperature, gelatin
302 dissolved in the same buffer (30 μL , 3.5 mg mL^{-1}) was added
303 and the mixture was incubated at $37 \text{ }^\circ\text{C}$. After 40 min, stop
304 reagent, containing 12 % (*m/V*) PEG 6000 and 25 mmol L^{-1}
305 EDTA was added, followed by 90 μL of the ninhydrin reagent.
306 The reaction mixture was incubated for 15 min at $80 \text{ }^\circ\text{C}$ and the
307 absorbance measured at 570 nm. The activity was calculated by
308 using the Equation 5:

$$\text{COLL} (\%) = \frac{A_{\text{control}} - A_{\text{sample}}}{A_{\text{control}}} \times 100, \quad (5)$$

309 where A_{control} is the absorbance of the negative control
310 (reaction mixture prepared with water instead of the extract) and
311 A_{sample} is the absorbance of the respective extract. Gallic acid was
312 used as the positive control.

313

314 *α -Amylase inhibition assay*

315 For α -amylase inhibition assay (aAM) (24) the extract
316 solution (0.5 mL) and phosphate buffer (0.5 mL, pH 6.9, 20
317 mmol L^{-1}), containing α -amylase from porcine pancreas (0.8 IU
318 mL^{-1}), were mixed and incubated at $25 \text{ }^\circ\text{C}$. After 10 min soluble
319 starch (0.5 mL, 0.5 % solution in the same buffer) was added and
320 the reaction mixture incubated at $25 \text{ }^\circ\text{C}$ for 10 min. The reaction
321 was stopped with 1 mL of 96 mmol L^{-1} 3,5-dinitrosalicylic acid,
322 and the reaction mixture incubated in a boiling water bath for 5
323 min. After cooling to room temperature, the reaction mixtures
324 were diluted with 10 mL distilled water and the absorbance was
325 measured at 540 nm. The activity was calculated as shown in
326 Equation 6:

$$\text{aAM (\%)} = \frac{A_{\text{control}} - A_{\text{sample}}}{A_{\text{control}}} \times 100, \quad (6)$$

327 where A_{control} is the absorbance of the negative control
328 (reaction mixture prepared with water instead of the extract) and
329 A_{sample} is the absorbance of the reaction mixture containing
330 extracts. Acarbose was used as the positive control.

331

332 *α -Glucosidase inhibition assay*

333 For inhibition of α -glucosidase determination (aGA) (25)
334 extract solution (20 μL) was incubated with 50 μL of α -
335 glucosidase from *Saccharomyces cerevisiae* (0.2 U mL^{-1}
336 dissolved in 0.1 mol L^{-1} phosphate buffer, pH 6.8) for 10 min at
337 37 °C. Substrate (50 μL of 1 mmol L^{-1} *p*-nitrophenyl- α -D-
338 glucopyranoside prepared in same buffer) was added to the
339 reaction mixture and the absorbance at 405 nm was recorded
340 after 5 min. The activity was calculated according to the
341 Equation 7:

$$\text{aGA (\%)} = \frac{A_{\text{control}} - A_{\text{sample}}}{A_{\text{control}}} \times 100, \quad (7)$$

342 where A_{control} is the absorbance of the negative control
343 (reaction mixture prepared with water instead of the extract) and
344 A_{sample} is the absorbance of the reaction mixture containing
345 extracts. Acarbose was used as the positive control.

346

347 *Statistical analysis*

348 The measurements were performed in triplicate and the
349 results presented as mean \pm standard deviation. Scavenging
350 activity for DPPH free radical, antioxidant activity in β -
351 carotene-linoleic acid assay, lipoxygenase inhibitory activity,
352 activity in the ovalbumin coagulation assay, collagenase
353 inhibitory activity, α -amylase inhibitory activity, and α -
354 glucosidase inhibitory activity were calculated as the
355 concentration of the extract that displays 50 % of the desired
356 activity (IC_{50}). Activity in the RP assay was calculated as the
357 concentration that increases the absorbance of reaction mixture

358 to the value of 0.5 at 700 nm ($EC_{0.5}$). For the ORAC assay a
359 standard curve was generated using Trolox of known
360 concentrations. The activity in the ORAC assay was calculated
361 as Trolox equivalents per gram of plant material ($\mu\text{mol TE g}^{-1}$
362 DM), while IC_{50} and $EC_{0.5}$ values were expressed as mass
363 concentration of plant material ($\mu\text{g DM mL}^{-1}$). For each assay,
364 four to seven different concentrations (depending on the assay)
365 were prepared using 2-fold dilution and used for determination
366 of the respective activity. The values were calculated using
367 regression analysis. The extracts that did not display observable
368 inhibitory activity in the performed assay, as well the extracts for
369 whom the calculated IC_{50} value in the respective assay was
370 higher than $5000 \mu\text{g DM mL}^{-1}$, were considered inactive and
371 excluded from the subsequent statistical analysis. Statistical
372 comparisons were performed using one-way ANOVA followed
373 by either Dunnett (comparisons of the individual extracts with
374 the controls) or Tukey (for comparisons between the extracts)
375 post-hoc tests. The differences between ethanolic and aqueous
376 extracts were investigated using paired t -test. Unless otherwise
377 noted, p values < 0.05 were considered statistically significant.
378 For overall comparison of the activity among the extracts, the
379 activity in each assay was normalized. First, the reciprocal value
380 of each IC_{50} value was calculated, while RP $EC_{0.5}$ and TE ORAC
381 values were used unchanged. The normalized values were
382 calculated as the percentage of the activity achieved by the most
383 active extracts. The normalized values were then summed for
384 each group of assays to give estimation of the overall most active
385 extracts.

386

387 RESULTS AND DISCUSSION

388 *Phenolic content of the extracts*

389 While some plants are cultivated specifically for the needs
390 of the food supplement industry, many are still collected in
391 nature. Each practice has its own drawbacks as the former

392 generates a significant amount of waste, while the latter has the
393 potential to damage natural resources and disrupt sensitive
394 ecological balance. On the other hand, utilizing existing
395 biowaste to obtain high-value products, such as food
396 supplements, may be a sustainable approach for their production.
397 In this regard, use of biowaste that remains as the residue after
398 mowing of urban parks, may be a promising approach as this
399 practice may generate a large amount of biomass mostly
400 discarded as waste (11).

401 In this study, six plants, representing the common waste
402 remaining after mowing urban parks in continental Europe, were
403 selected for screening. Aerial parts of some of the plants
404 investigated in this study are commonly used as traditional
405 antidiabetics in Croatia (AM and CI) (26), or other countries
406 (MS, TPr) (8, 27), while the specific antidiabetic
407 ethnopharmacological use of the leaves, flowers and the stems
408 of the others (MSy, PL) has not been recorded so far. A common
409 feature of the plants used in this study is that they are often
410 undervalued and underutilized, yet have the means of potentially
411 creating novel, value-added, food and supplements. Previous
412 studies identified them as rich sources of natural phenols
413 including hydroxycinnamic acid derivatives and natural
414 flavonoids (28). This is of particular interest as natural phenols
415 deservedly keep their place in the spotlight of scientific research
416 of diabetes. They exhibit a variety of beneficial effects related to
417 the prevention of T2D and associated complications. Phenolics
418 are recognized for their antioxidant and anti-inflammatory
419 properties that contribute to the reduction of oxidative stress
420 resulting from elevated glucose levels in T2D. They also have
421 the potential to inhibit digestive enzymes that influence glucose
422 levels in the blood, such as α -glucosidases and α -amylase. A
423 significant number of their effects is, directly or indirectly,
424 linked to the protection of pancreatic β -cells against glucose-
425 induced toxicity, stimulation of the insulin production, and

426 reduction of insulin resistance (7). All this may result in the
427 prevention of secondary T2D complications as it has been
428 repeatedly shown that consumption of phenolic-rich foods
429 contributes to protection of the eye, kidney, and liver the organs
430 most sensitive secondary complications in T2D (4).

431 In this work, TP content, as well as the content of the two
432 widely distributed groups of phenols, flavonoids (TF), and
433 hydroxycinnamic acids (TCA), was investigated and presented
434 in Table II. In order to estimate the effects and influence of
435 individual flavonoids and hydroxycinnamic acids on the
436 potential antidiabetic effects of the extracts, HPLC analysis was
437 used and the results presented in Table III. While the extracts
438 were quite rich in the phenolic compounds, significant
439 differences were present among extracts (Table II). Richest in
440 TP was CI50 ($274.81 \pm 7.31 \text{ mg CAE g}^{-1} \text{ DM}$), closely followed
441 by MS50. TP content was the lowest in the MSy based extracts,
442 MSy10, and MSy50 ($102.34 \pm 3.14 \text{ mg CAE g}^{-1} \text{ DM}$ and 128.91
443 $\pm 8.39 \text{ mg CAE g}^{-1} \text{ DM}$, respectively).

444 Hydroxycinnamic acids are among the most ubiquitous
445 phenolic compounds in nature. They largely belong to the group
446 of phenolic acids, and similar to other phenolics, they have the
447 ability to influence glucose metabolism by several mechanisms,
448 such as inhibition of carbohydrate digestion, stimulation of
449 insulin secretion from the pancreatic β -cells, modulation of
450 glucose release and output from liver, as well as by the activation
451 of glucose uptake in insulin-sensitive tissues (29). The results
452 presented in Table II show that the prepared extracts contained
453 considerable amounts of TCA. They constituted up to 70 % of
454 TP in PL extracts, and about 50 % in AM extracts. Among the
455 analyzed extracts, TCA content was highest in the extracts
456 prepared from *P. lanceolata*, PL50 ($165.4 \pm 1.45 \text{ mg CAE g}^{-1}$
457 DM) and PL10 ($138.14 \pm 2.38 \text{ mg CAE g}^{-1} \text{ DM}$). Again, MSy10
458 and MSy50 were the extracts with the lowest amount of TCA

459 (19.74 ± 1.79 mg CAE g⁻¹ DM and 21.32 ± 1.91 mg CAE g⁻¹
460 DM, respectively).

461 Among the hydroxycinnamic acids, the most widespread
462 and often analyzed for their antidiabetic activities are CA
463 derivatives. Pharmacological studies have shown that dietary
464 supplementation with CA lowers blood glucose and enhances
465 insulin levels in diabetic mice. In addition, it reduces the levels
466 of plasma HbA1c, urinary glycated albumin, renal
467 carboxymethyl lysine, pentosidine, sorbitol, and fructose levels,
468 as well as significantly diminishes renal activity of aldose
469 reductase and sorbitol dehydrogenase (29). As shown in Table
470 III, CA was found in the extracts prepared from AM, PL and TPr,
471 however in relatively small quantities (up to 0.205 mg g⁻¹ DM
472 in AM-10).

473 Phenolic compounds in plant materials typically exist in the
474 form of glycosides or esters. Nevertheless, the aglycon type is
475 the primary factor that influences the pharmacological effects of
476 flavonoids, phenolic acids, and their respective preparations
477 (30). Therefore, the presence of some common CA derivatives
478 was also assessed. First among them was NcA, a phenolic acid
479 with a significant antidiabetic potential. It is the main compound
480 of mulberry leaf extract, a well-known antidiabetic remedy in
481 many countries, including Croatia (31). Recent studies have
482 shown that both, mulberry leaf extract and NcA, were able to
483 ameliorate glucolipotoxicity-induced diabetic nephropathy in
484 high-fat diet-fed diabetic mice (32). In this work, NcA was
485 present in the same extracts as CA, albeit in similarly low
486 quantities (Table III). The richest among them was PL50,
487 containing 1.510 mg g⁻¹ DM of this phenolic acid. On the other
488 hand, RA, a CA derivative similarly beneficial in the
489 amelioration of diabetic neuropathy in rats (29), was present just
490 in the extracts prepared from AM, mostly in AM50 (7.722 mg g⁻¹
491 DM).

492 *Table II. Content of phenolic compounds and antioxidant activity of the extracts*

Extract	TP (mg CAE g ⁻¹ DM)	TCA (mg CAE g ⁻¹ DM)	TF (mg QE g ⁻¹ DM)	RSA IC ₅₀ (μg g ⁻¹ DM)	ACLA IC ₅₀ (μg g ⁻¹ DM)	RP EC _{0.5} (μg g ⁻¹ DM)	ORAC (μmol TE g ⁻¹ DM)
AM10	154.86 ± 6.25 ^{f,g}	68.03 ± 2.36 ^g	16.77 ± 0.68 ^{f,g}	75.73 ± 1.27 ^{d,x}	39.38 ± 0.88 ^{f,x}	0.32 ± 0.04 ^{d,x}	1943.55 ± 229.93 ^h
AM50	208.38 ± 11.74 ^d	108.57 ± 0.27 ^d	45.49 ± 0.42 ^b	40.88 ± 2.89 ^{h,i,x}	37.26 ± 0.46 ^{f,x}	0.20 ± 0.02 ^{e,f,x}	4785.37 ± 280.08 ^{b,c}
CI10	217.84 ± 1.93 ^{c,d}	85.07 ± 1.88 ^e	58.8 ± 2.87 ^a	66.93 ± 0.76 ^{e,x}	57.51 ± 1.64 ^{a,x}	0.18 ± 0.01 ^{e,f,g,h,x}	3503.36 ± 293.10 ^{e,f}
CI50	274.81 ± 7.31 ^a	119.95 ± 4.00 ^c	61.09 ± 2.21 ^a	32.73 ± 2.22 ^{i,j,x}	39.44 ± 0.47 ^{f,x}	0.13 ± 0.01 ^{g,h,y}	5368.23 ± 412.84 ^b
MS10	149.57 ± 1.88 ^g	21.82 ± 0.85 ^j	19.63 ± 0.40 ^{e,f}	69.68 ± 0.28 ^{d,e,x}	31.54 ± 2.80 ^{g,x}	0.20 ± 0.01 ^{e,f,g,x}	3968.58 ± 235.63 ^{c,d,e}
MS50	268.97 ± 6.08 ^a	40.29 ± 1.52 ^h	29.27 ± 0.89 ^c	26.94 ± 0.46 ^{j,x}	40.64 ± 0.56 ^{e,f,x}	0.12 ± 0.02 ^{h,y}	4726.89 ± 307.99 ^{b,c}
MSy10	102.34 ± 3.14 ⁱ	19.74 ± 1.79 ^j	9.98 ± 0.14 ⁱ	229.74 ± 6.91 ^{a,x}	52.77 ± 0.37 ^{b,x}	0.39 ± 0.05 ^{c,x}	3044.79 ± 285.36 ^{f,g}
MSy50	128.91 ± 8.39 ^h	21.32 ± 1.91 ^j	15.17 ± 0.32 ^{g,h}	173.6 ± 2.99 ^{b,x}	48.46 ± 2.94 ^{c,d,x}	0.44 ± 0.02 ^{b,c,x}	4659.76 ± 269.22 ^{b,c}

PL10	200.77 ± 2.71 ^d	138.14 ± 2.38 ^b	17.86 ± 0.17 ^f	43.00 ± 3.30 ^{g,h,x}	39.27 ± 0.83 ^{f,x}	0.19 ± 0.01 ^{e,f,g,h,x}	2188.12 ± 320.92 ^{g,h}
PL50	234.41 ± 7.59 ^{b,c}	165.4 ± 1.45 ^a	23.7 ± 0.80 ^d	41.33 ± 1.42 ^{h,x}	40.31 ± 0.39 ^{f,x}	0.15 ± 0.01 ^{f,g,h,y}	5434.69 ± 170.57 ^b
TPr10	129.47 ± 6.66 ^h	32.07 ± 0.98 ⁱ	14.31 ± 1.02 ^h	109.28 ± 3.46 ^{e,x}	52.34 ± 1.32 ^{b,c,x}	0.52 ± 0.03 ^{a,x}	3779.84 ± 396.76 ^{d,e,f}
TPr50	176.26 ± 6.63 ^e	75.84 ± 5.72 ^f	29.4 ± 0.52 ^c	50.86 ± 1.96 ^{f,g,x}	46.05 ± 0.86 ^{d,x}	0.22 ± 0.01 ^{e,x}	7354.71 ± 365.39 ^a
Standar d				(¹) 9.58 ± 0.38 ^y	(¹) 2.03 ± 0.05 ^y	(²) 0.12 ± 0.03 ^y	

493 TP – total phenols, CAE – caffeic acid equivalents, DM – dry mass of the extract, TCA – total hydroxycinnamic acids, TF – total flavonoids, QE
 494 – quercetin equivalents, RSA – scavenging activity for 2,2-diphenyl-1-picrylhydrazyl free radical, IC_{50} – concentration that produces 50 % of the
 495 inhibition in the assay, ACLA – antioxidant activity in β -carotene-linoleic acid assay, RP – reducing power, $EC_{0.5}$ – concentration used in the
 496 assay that produces the absorption of 0.5, ORAC – oxygen radical absorbance capacity, TE – Trolox equivalents; The extracts' names abbreviations
 497 are explained in the Experimental section “Preparation of the extracts”.

498 Standards: (¹) = Butylated hydroxyanisole, (²) = Ascorbic acid.

499 ^{a-j} = Differences between the extracts within a column (extracts not connected with the same capital letter are statistically different, Tukey post-
 500 test, $p < 0.05$); ^{x,y} = differences with the positive control within a column (extracts not connected with the same capital letter are statistically
 501 different, Dunnet's post-test, $p < 0.05$). Values are average of 3 replications ± SD.

502 Conversely, ChA was by far the most widespread CA derivative,
503 being present in all the analyzed extracts in relatively high
504 quantities. This finding is not unexpected because ChA is one of
505 the most abundant phenolic compounds in nature. It is widely
506 considered that numerous benefits of coffee consumption,
507 including lower risk of T2D, are related to its ChA content. T2D-
508 related benefits of ChA include attenuation of the intestinal
509 absorption of glucose, regulation of glucose metabolism via the
510 activation of AMP-activated protein kinase, and improvement of
511 insulin sensitivity through an adiponectin receptor-mediated
512 signaling pathway (29). AM extracts were especially rich in
513 ChA, especially AM-50 with the content of 23.332 mg g⁻¹ DM.

514 Phenylpropanoid glycoside verbascoside (acteoside) is a
515 CA derivative that doesn't belong to the group of phenolic acids.
516 It is present in various plants, most notably in olive fruit and leaf
517 (*Olea europea* L, Oleaceae) where it is considered to largely
518 contribute to the benefits of their consumption. PL is also a plant
519 that is known to contain large amounts of this glycoside (33).
520 Accordingly, it was present in rather high quantities in the
521 extracts prepared from PL, especially in PL50 (453.7 mg g⁻¹
522 DM) (Table III). The amount of verbascoside in PL extracts
523 seemingly outweighed the TP content (Table II). The apparent
524 discrepancy was due to CA being used as a standard for
525 determination of TP in all the extracts in this work. As its
526 molecular mass is 3.5-fold lower than that of verbascoside, the
527 calculated results gave seemingly lower mass of TP. In various
528 studies verbascoside demonstrated various pharmacological
529 activities related to diabetes, including antioxidant and anti-
530 inflammatory, as well as neuro- and hepato-protective activity.
531 It also reduced glucose absorption rate through inhibition of both
532 α -amylase and sodium-dependent glucose cotransporter 1
533 (SGLT1)-mediated glucose absorption in Caco-2 cells. In
534 addition, verbascoside may protect β -cells against oxidative
535 stress (34).

536 Another group of phenolics whose consumption may be
537 connected to the prevention of T2D and other chronic diseases
538 are flavonoids. Flavonoids may protect against high glucose
539 levels by increasing insulin secretion and enhancing insulin
540 sensitivity. They may also lower oxidative stress, prevent
541 pancreatic β -cells from undergoing apoptosis, and reduce
542 diabetes risk factors by regulating the major pathways for
543 carbohydrate metabolism and hepatic glucose homeostasis (7).
544 As for TF content (Table II), CI50 and CI10 were the extracts
545 with their highest amount (61.09 ± 2.21 mg QE g^{-1} DM and 58.8
546 ± 2.87 mg QE g^{-1} DM, respectively), whereas MSy10 contained
547 the least TF (9.98 ± 0.14 mg QE g^{-1} DM). In general, TF content
548 constituted around 10 % of TP in most the extracts, a notable
549 exception being CI extracts where they reached as much as 20 %
550 share.

551 The results revealed that the extracts contained several
552 common flavonoids such as apigenin, luteolin, and quercetin
553 derivatives (Table III). Among them Q and its derivatives have
554 received the most attention for their antidiabetic properties.
555 Quercetin and consequently its derivatives may reduce
556 hyperglycemia and liver glucose content. They may also
557 improve glucose tolerance, hepatic glucokinase activity, release
558 of insulin, and pancreatic cell regeneration, to name a few (7).
559 While small amounts of free quercetin were present only in MSy
560 extracts, the quantities of its glycosides were much higher. Most
561 frequent among them was H present in AM, MS, and TPr
562 extracts. Most abundant among them was MS50 with 7.738 mg
563 H g^{-1} DM. Qcit, on the other hand, was present only in MS and
564 MSy extracts. Again, MS50 was the richest in Qcit with as much
565 as 8.677 mg Qcit g^{-1} DM. IQ was present only in TPr extracts
566 with maximum of 2.340 mg g^{-1} DM in TPr50.

567 *Table III. Content of the selected phenolics in the extracts*

Extract	Caffeic acid derivatives (mg g ⁻¹ DM)	Apigenin derivatives (mg g ⁻¹ DM)	Luteolin derivatives (mg g ⁻¹ DM)	Quercetin derivatives (mg g ⁻¹ DM)
AM-10	0.205 (CA), 22.091 (ChA), 0.793 (NcA), 2.842 (RA)	0.440 (A), 0.124 (A7G)	0.561 (L), 3.625 (L7G)	2.278 (H)
AM-50	0.164 (CA), 23.332 (ChA), 0.683 (NcA), 7.722 (RA)	0.821 (A), 0.441 (A7G)	1.268 (L), 4.348 (L7G)	2.580 (H)
CI-10	12.103 (ChA)		0.692 (L7G)	
CI-50	15.054 (ChA)		0.794 (L7G)	
MS-10	2.087 (ChA)			3.572 (H), 3.717 (Qcit)
MS-50	3.359 (ChA)			7.738 (H), 8.677 (Qcit)
MSy-10	0.807 (ChA)	0.382 (A)		0.495 (Q), 0.637 (Qcit)
MSy-50	1.270 (ChA)	0.663 (A)		0.657 (Q)
PL-10	0.076 (CA), 2.187 (ChA), 1.430 (NcA), 329.800 (V)		0.219 (L)	
PL-50	0.085 (CA), 2.233 (ChA), 1.510 (NcA), 453.700 (V)		0.135 (L)	
TPr-10	0.154 (CA), 0.981 (ChA), 0.133 (NcA)			1.299 (H), 0.813 (IQ)

TPr-50 0.056 (CA), 1.382 (ChA), 0.270 (NcA)

0.606 (A7G)

4.272 (H), 2.340 (IQ)

568 CA – caffeic acid, ChA –chlorogenic acid, NcA – neochlorogenic acid, RA – rosmarinic acid, V – verbascoside, L – luteolin, L7G – luteolin-7-*O*-
569 glucoside, Q – quercetin as dehydrate, H – hyperosid, IQ – isoquercetin, Qcit – quercitrin as dehydrate, A – apigenin, A7G – apigenin-7-*O*-
570 glucoside, DM – dry mass of the extract. The extracts' names abbreviations are explained in the Experimental section “Preparation of the extracts”.
571

Uncorrected proof

572 Apigenin and its derivatives also may have a significant
573 antidiabetic potential as it was shown that it may improve renal
574 dysfunction and oxidative stress, decrease blood glucose and
575 stimulate glucose induced insulin secretion (35). However,
576 apigenin and its derivatives were present in relatively small
577 amounts in the prepared extracts. Only AM and MSy extracts
578 contained A, the highest content being 0.821 mg/g DM in AM50.
579 Similarly, A7G was present in AM extracts and TPr50, the latter
580 containing the most of this glycoside (0.606 mg g⁻¹ DM).
581 Content of luteolin derivatives in the extracts, on the other hand,
582 was somewhat higher (1.268 mg g⁻¹ DM of L and 4.348 mg g⁻¹
583 DM of L7G, both in AM-50). Luteolin also shows an interesting
584 antidiabetic potential. Cumulative evidence indicates that
585 luteolin may be considered as a regulator of insulin resistance in
586 diabetes because it positively affects gluconeogenic and
587 lipogenic capacity (36).

588 It should be noted that 50 % ethanol was overall a better
589 solvent than 10 % ethanol for the extraction of all the
590 investigated phenolics as its use resulted in statistically higher
591 yields (paired *t*-test, *p* < 0.05) of TP, TCA, and TF. This is
592 probably due to the lower polarity of 50 % ethanol as compared
593 to 10 % ethanol, which was apparently more suitable for
594 dissolving the tested phenolic substances. The difference,
595 however, was not that high, as the ratios of the average contents
596 of selected phenolics obtained using 50 % ethanol and 10 %
597 ethanol ranged from 1.35 (TP) to 1.48 (TF). In general, the
598 results obtained in this work are in line with the results of some
599 previous studies that compared the content of phenols and
600 flavonoid in the investigated plants e.g. for AM (37). While the
601 presence of some of the selected phenolic standards confirms
602 previous reports (*e.g.* ChA in CI, PL, TPr, CA, hyperosid and
603 verbascoside in PL, the other previously reported compounds
604 were not recorded in this work (*e.g.* apigenin and A7O in PL)
605 (28). This may be related either to the interspecies variations (38)

606 or the specific conditions of extracts' preparation. This finding
607 further stresses the well-known necessity of the standardization
608 of herbal material used for preparation of plant-based products
609 including those intended for T2D treatment (39).

610

611 *Antioxidant activity of the extracts*

612 Constant hyperglycemia, the hallmark of T2D, may
613 contribute to the formation of advanced glycation end-products,
614 the activation of protein kinase C, mitochondrial dysfunction,
615 and ultimately the accumulation of ROS. Although ROS are
616 essential for healthy metabolic processes at physiological levels,
617 an overproduction of ROS can induce oxidative stress that
618 further induces damage to cellular macromolecules, disruption
619 of protein function, and, ultimately, cell death (4). A persistent
620 condition of increased oxidative stress in T2D contributes to the
621 onset of diabetic complications such as nephropathy,
622 neuropathy, retinopathy, and liver damage (3, 4). Such state may
623 be ameliorated by using various endogenous and exogenous
624 antioxidants leading researchers to believe that the main benefit
625 of herbal products in relation to T2D may be found primarily in
626 the area of prevention of diabetic complications (40). The
627 antioxidant properties of plant secondary metabolites can occur
628 through different mechanisms, such as the transfer of hydrogen
629 atoms or single electrons. The proportion of each of those
630 mechanisms in total antioxidant activity of an herbal extract
631 depends on various influences. Consequently, it is often rational
632 to employ multiple methods to achieve a thorough evaluation of
633 the antioxidant activity of complex mixtures, such as herbal
634 extracts (41). In this work, antioxidant activity of the extracts
635 was assessed and compared using RSA, ACLA, RP, and ORAC
636 assay (Table II).

637 The data presented in Table II indicate moderate to
638 relatively good antioxidant activity of the extracts in the RSA
639 assay. Yet, none of the extracts reached the activity of the

640 antiradical standard, BHA (IC_{50} of $9.58 \pm 0.38 \mu\text{g g}^{-1}$ DM). The
641 best RSA (indicated by the lowest IC_{50} value) was displayed by
642 CI50 and MS50 with IC_{50} values being $32.73 \pm 2.22 \mu\text{g g}^{-1}$ DM
643 and $26.94 \pm 0.46 \mu\text{g g}^{-1}$ DM, respectively. The activity in this
644 assay correlated statistically significantly with the TP and TCA
645 content with $R^2 = 0.652$ ($p = 0.0015$) and $R^2 = 0.400$ ($p = 0.0273$)
646 for TP and TCA, respectively. This indicates an important role
647 that the phenolic compounds play in the radical scavenging
648 activity of the extracts. Similar to the phenolic content, 50 %
649 ethanol was found to be a better solvent for preparation of the
650 extracts with high RSA, as its application resulted in the extracts
651 displaying statistically lower IC_{50} values in this assay (paired t -
652 test, $p < 0.05$). Unlike RSA, ACLA assay did not show any
653 correlation with the content of the investigated phenolics, nor
654 was the activity connected with the solvent used for the
655 extraction. The most active in the ACLA assay was MS10 (IC_{50}
656 = $31.54 \pm 2.80 \mu\text{g g}^{-1}$ DM), but its activity did not quite reach
657 that of the standard, BHA ($IC_{50} = 2.03 \pm 0.05 \mu\text{g g}^{-1}$ DM).

658 RP activity, on the other hand, was rather well pronounced
659 in all the tested extracts. The most active extracts were CI50
660 ($EC_{0.5} = 0.13 \pm 0.01 \mu\text{g g}^{-1}$ DM), MS50 ($EC_{0.5} = 0.12 \pm 0.02 \mu\text{g}$
661 g^{-1} DM), and PL50 ($EC_{0.5} = 0.15 \pm 0.01 \mu\text{g g}^{-1}$ DM), whose
662 activity did not differ from the activity of the reducing standard,
663 ascorbic acid ($EC_{0.5} = 0.12 \pm 0.03$). Similar to RSA assay,
664 phenolic compounds contributed highly to the activity in RP
665 assay, as the RP activity correlated significantly with their
666 content ($R^2 = 0.7094$, $p = 0.0006$ for TP, $R^2 = 0.3707$, $p = 0.0356$
667 for TCA; and $R^2 = 0.3551$, $p = 0.0409$ for TF). This was not
668 surprising having in mind that natural flavonoids and other
669 phenols possess reducing abilities (42). The correlation between
670 RSA and RP ($R^2 = 0.5957$, $p = 0.0033$), that was also observed,
671 is probably due to similar underlying reasons. Finally, the
672 extracts displayed excellent ORAC activity with TPr50 being by
673 far the most active among the tested extracts (7354.71 ± 365.39

674 $\mu\text{mol TE g}^{-1}\text{ DM}$). Similar to RSA and RP assays, 50 % ethanol
675 was better suited for the preparation of the extracts with high
676 ORAC activity than 10 % ethanol (paired *t*-test, $p < 0.05$).
677 Relatively good activity of several plants in the performed assays
678 has been previously recorded (43) but the overall comparison of
679 normalized activities showed that MS50, TPr50, and CI50
680 scored highest in the performed tests.

681

682 *Anti-inflammatory and collagenase-inhibitory activity*

683 One of the key features of T2D is chronic inflammation that
684 is observed in various tissues. It is directly involved in long-term
685 complications of diabetes, including cardiovascular disease,
686 nephropathy, retinopathy, and non-alcoholic fatty liver disease.
687 Furthermore, chronic inflammation in T2D is associated with
688 other conditions whose frequency is higher in patients suffering
689 from the disease, such as rheumatoid arthritis, gout or even
690 Alzheimer's disease (2). In this work, the anti-inflammatory
691 potential of the prepared extracts was investigated by using three
692 assays. The first was LOX-inhibition assay. LOX is the enzyme
693 involved in the metabolism of arachidonic acid and the release
694 of various pro-inflammatory eicosanoid substances, such as
695 leukotrienes and lipoxins. It mediates inflammatory events that
696 result from various environmental factors including sun
697 radiation, inflammation mediators, and allergens (44). Among
698 the extracts tested in this work, MS10 was the most potent LOX-
699 inhibitor with IC_{50} value being $45.03 \pm 1.08 \mu\text{g g}^{-1}\text{ DM}$, which
700 was still weaker than the activity of NDGA ($IC_{50} = 2.96 \pm 0.33$
701 $\mu\text{g g}^{-1}\text{ DM}$) (Table IV). It seems that natural products with high
702 antioxidant capacity are important for LOX-inhibition activity as
703 the activity in this assay correlated statistically significant with
704 TP ($R^2 = 0.4341$, $p = 0.0198$), RSA ($R^2 = 0.8558$, $p = 0.0004$),
705 ACLA ($R^2 = 0.5062$, $p = 0.0095$) and RP ($R^2 = 0.7056$, $p =$
706 0.0006). Strong correlation of LOX-inhibition activity with RSA
707 and other antioxidant assays is in line with the redox mechanism

708 of LOX-inhibition activity, as LOX isoenzymes catalyze the
709 stereospecific catalysis and oxygenation of polyunsaturated fatty
710 acids to their hydroperoxy derivatives (45).

711 The second assay used in this work investigated the ability
712 of the extracts to inhibit the heat-induced protein coagulation
713 (Table IV). Denaturation of tissue proteins is one of the
714 characteristics and causes of inflammatory processes. Therefore,
715 its suppression may hinder the development of tissue changes
716 which are another important aspect of inflammatory processes
717 (22). The extracts displayed excellent activities in this assay,
718 with several among them reaching the activity of the standard
719 inhibitor, diclofenac sodium ($IC_{50} = 114.66 \pm 2.40 \mu\text{g g}^{-1} \text{DM}$).
720 The most active was MSy50 ($IC_{50} = 80.09 \pm 7.35 \mu\text{g g}^{-1} \text{DM}$),
721 while the others (CI10, CI50, MS50, Msy10) displayed
722 statistically equal activity with values IC_{50} that ranged from
723 $108.10 \pm 3.07 \mu\text{g g}^{-1} \text{DM}$ to $137.15 \pm 9.42 \mu\text{g g}^{-1} \text{DM}$.

724 Collagenases belong to a larger group of matrix
725 metalloproteinases (MMPs), enzymes that are involved in the
726 development and healing of diabetic wounds. The management
727 of wounds in diabetic patients presents significant challenges, as
728 these wounds are linked to lower life quality and expectancy.
729 One of the fundamental factors contributing to the chronic nature
730 of diabetic wounds is the persistent state of inflammation
731 occurring within the organism of diabetic patients. An excess of
732 proinflammatory cytokines prompts fibroblasts to produce an
733 overabundance of MMPs, which in turn degrade both nonviable
734 and viable collagen fibers (46). Collagenase-inhibiting
735 properties of the extracts are presented in Table IV. Most
736 extracts displayed an excellent anti-collagenase activity with
737 IC_{50} values that did not differ from that of the employed
738 standard, gallic acid ($IC_{50} = 127.82 \pm 5.20 \mu\text{g g}^{-1} \text{DM}$). The most
739 active among them was TPr50 with $IC_{50} = 73.58 \pm 0.74 \mu\text{g/g}$
740 DM. Collagenase-inhibitory activity correlated significantly
741 with TP ($R^2 = 0.4341$, $p = 0.0198$), designating phenolic

742 compounds as potentially significant contributors to this aspect
743 of the activity of the prepared extracts.

744 Among the tested extracts CI50, MS50, and CI10 showed
745 the best overall activity in the three performed assays, while
746 CI50, MSy50, and MS10 were the most active in the two assays
747 more closely related to the anti-inflammatory activity (LOXI and
748 OVA). Interestingly, a literature report states that the sprouts of
749 MS (47) did not contain lipoxygenase inhibitors. Thus, the
750 excellent activity demonstrated in this study is probably related
751 to the metabolites that develop in the later stages of plant growth.
752 While MSy was not, to the best of our knowledge, previously
753 investigated using the applied assays, previous studies have
754 shown that the hairy roots of CI were an excellent source of anti-
755 LOX compounds (48). However, to the best of our knowledge,
756 this is the first report on the activity of the aerial parts of CI for
757 anti-LOX activity. Interestingly, in a study investigating anti-
758 collagenase and anti-elastase activities of extracts from 21
759 plants, MS was found devoid of the activity (49), a result directly
760 opposing strong activity of the plant recorded in this work. While
761 CI (50), and MSy (51) have well-documented wound healing
762 activities, neither of them was specifically tested for anti-
763 collagenase activity. Thus, this work may be a constructive
764 addition to the research on their possible mechanism of action.

765 Table IV. Antiinflammatory and antidiabetic activity of the extracts

Extract	LOXI IC_{50} ($\mu\text{g g}^{-1}$ DM)	OVA IC_{50} ($\mu\text{g g}^{-1}$ DM)	COLL IC_{50} ($\mu\text{g g}^{-1}$ DM)	aAM IC_{50} ($\mu\text{g g}^{-1}$ DM)	aGL IC_{50} ($\mu\text{g g}^{-1}$ DM)
AM10	$168.72 \pm 5.36^{\text{d,x}}$	$632.67 \pm 43.54^{\text{c,d,x}}$	$138.38 \pm 19.37^{\text{b,c,y}}$	<i>n.a.</i>	<i>n.a.</i>
AM50	$91.69 \pm 3.87^{\text{h,x}}$	$523.66 \pm 79.08^{\text{d,x}}$	$269.73 \pm 8.09^{\text{b,c,y}}$	$2100.64 \pm 217.90^{\text{b,x}}$	$828.33 \pm 32.96^{\text{b,c,x}}$
CI10	$171.44 \pm 13.79^{\text{d,x}}$	$137.15 \pm 9.42^{\text{d,y}}$	$109.25 \pm 1.09^{\text{b,c,y}}$	<i>n.a.</i>	<i>n.a.</i>
CI50	$114.79 \pm 7.82^{\text{g,h,x}}$	$108.10 \pm 3.07^{\text{d,y}}$	$84.24 \pm 11.79^{\text{b,c,y}}$	$2344.83 \pm 147.50^{\text{b,x}}$	$1122.62 \pm 61.78^{\text{b,x}}$
MS10	$45.03 \pm 1.08^{\text{i,x}}$	$1488.35 \pm 56.45^{\text{a,x}}$	$2883.77 \pm 346.05^{\text{a,x}}$	$204.10 \pm 2.11^{\text{c,d,y}}$	$11.29 \pm 0.07^{\text{d,y}}$
MS50	$146.26 \pm 7.05^{\text{f,g,x}}$	$116.01 \pm 6.24^{\text{d,y}}$	$102.12 \pm 15.32^{\text{b,c,y}}$	$78.27 \pm 0.99^{\text{d,y}}$	$3.21 \pm 0.04^{\text{d,y}}$
MSy10	$468.61 \pm 15.14^{\text{a,x}}$	$118.57 \pm 5.86^{\text{d,y}}$	$379.48 \pm 22.77^{\text{b,x}}$	<i>n.a.</i>	<i>n.a.</i>
MSy50	$355.17 \pm 18.09^{\text{c,x}}$	$80.09 \pm 7.35^{\text{d,y}}$	$197.89 \pm 27.70^{\text{b,c,y}}$	$4884.79 \pm 462.98^{\text{a,x}}$	$2584.71 \pm 328.60^{\text{a,x}}$
PL10	$191.43 \pm 8.91^{\text{d,x}}$	$362.55 \pm 36.00^{\text{e,x}}$	$106.95 \pm 8.56^{\text{b,c,y}}$	<i>n.a.</i>	<i>n.a.</i>
PL50	$156.45 \pm 12.18^{\text{d,e,f,x}}$	$840.08 \pm 116.63^{\text{b,x}}$	$110.94 \pm 8.88^{\text{b,c,y}}$	<i>n.a.</i>	$2314.91 \pm 461.05^{\text{a,x}}$
TPr10	$412.46 \pm 13.34^{\text{b,x}}$	$703.14 \pm 0.76^{\text{b,x}}$	$165.96 \pm 1.66^{\text{b,c,y}}$	$740.43 \pm 26.28^{\text{c,x}}$	$367.3 \pm 4.43^{\text{c,d,y}}$
TPr50	$149.75 \pm 19.88^{\text{e,f,g,x}}$	$693.52 \pm 60.23^{\text{b,c,x}}$	$73.58 \pm 0.74^{\text{b,c,y}}$	$552.22 \pm 14.10^{\text{c,y}}$	$240.83 \pm 9.75^{\text{d,y}}$
Standard	$^{(1)} 2.96 \pm 0.33^{\text{y}}$	$^{(2)} 114.66 \pm 2.40^{\text{y}}$	$^{(3)} 127.82 \pm 5.20^{\text{y}}$	$^{(4)} 284.74 \pm 3.81^{\text{y}}$	$^{(4)} 168.13 \pm 0.46^{\text{y}}$

766 DM – dry mass of the extract, LOXI – lipoxygenase inhibitory activity, OVA – activity in the ovalbumin coagulation assay, COLL – collagenase
767 inhibitory activity, aAM – α -amylase inhibitory activity aGL – α -glucosidase inhibitory activity, *n.a.* – no activity. Standards: ⁽¹⁾
768 nordihydroguaiaretic acid, ⁽²⁾ diclofenac sodium, ⁽³⁾ gallic acid, ⁽⁴⁾ acarbose.

769 ^{a-i} Differences between the extracts within a column (extracts not connected with the same capital letter are statistically different, Tukey post-test,
770 $p < 0.05$); ^{x,y} differences with the positive control within a column (extracts not connected with the same capital letter are statistically different,
771 Dunnet's post-test, $p < 0.05$). Values are average of 3 replications \pm SD.

772

Uncorrected proof

773 *Inhibiting activity on α -amylase- and α -glucosidase*

774 Antihyperglycaemic potential of the extracts was
775 investigated by studying their potential to inhibit two enzymes
776 involved into carbohydrate digestion: α -glucosidase and α -
777 amylase. Numerous plant-derived secondary metabolites have
778 the potential to influence critical enzymes involved in
779 carbohydrate metabolism, thereby slowing the rise of
780 postprandial glucose levels. The enzyme α -amylase is produced
781 in the saliva and pancreatic juice. It facilitates the hydrolysis of
782 starch into a mixture of oligosaccharides, which are
783 subsequently broken down into glucose by α -glucosidase, the
784 enzyme found in the mucosal brush border of the small intestine.
785 Traditional medicinal plants are particularly abundant in α -
786 amylase and α -glucosidase inhibitors, rendering them significant
787 nutritional and therapeutic resources for the prevention of long-
788 term complications associated with T2D, obesity, and
789 hyperlipidemia (5, 52). The extracts investigated in this work
790 displayed similar and rather notable inhibition of these two
791 enzymes (Table IV).

792 While some extracts did not adversely affect the activity of
793 the α -amylase in the respective assay, several extracts
794 demonstrated high activity. Most active were the extracts
795 prepared from the Fabaceae family, namely MS10, MS50, and
796 TPr50. Their activity did not statistically differ from the activity
797 of acarbose. Especially active was the MS50 whose IC_{50} value
798 was 3.6-fold lower than then IC_{50} value of acarbose (78.27 ± 0.99
799 $\mu\text{g/g DM}$ vs. $284.74 \pm 3.81 \mu\text{g/g DM}$). Similarly, the two extracts
800 prepared from the same plants excelled as α -glucosidase-
801 inhibitors. Superior activity was observed by MS10 ($IC_{50} =$
802 $11.29 \pm 0.07 \mu\text{g/g DM}$), and MS50 ($IC_{50} = 3.21 \pm 0.04 \mu\text{g/g DM}$),
803 whose IC_{50} values were 15- and as much as 52-fold lower than
804 IC_{50} value of acarbose. An association of α -glucosidase-
805 inhibiting assay with the activity in the ORAC assay was found

806 but it was rather low ($R^2 = 0.5318$, $p = 0.0401$). However, the
807 activity in α -glucosidase-inhibiting assay was rather strongly
808 correlated with α -amylase-inhibiting activity ($R^2 = 0.8269$, $p =$
809 0.0045) indicating either the similar underlying mechanisms of
810 the two assays or the presence of chemically similar inhibitors in
811 the tested extracts.

812 Interestingly, while in this study MSy extracts displayed
813 either weak or no discernible activity, a in a study performed on
814 samples from Palestine, hydrophilic fractions of the plant
815 exhibited a remarkable α -amylase inhibitory activity (53). The
816 discrepancy could be attributed to differences in chemical
817 composition that occur in different geographical regions as it has
818 been noted that chemical composition and biological activity of
819 MSy is strongly influenced by altitude, fertility of soil, and water
820 supply, even when growing in close geographic areas (38).
821 Overall, the best combined inhibition was observed by MS50,
822 MS10, and TPr50 extract. Previous studies of MS (43), CI, and
823 TPr extracts (8) demonstrated moderate antidiabetic activity in
824 the two assays. However, the excellent activity presented in this
825 work is, in addition to the chemical interspecies diversity,
826 possibly a consequence of the selected solvent and/or the
827 extraction method (*e.g.* ultrasonication *vs.* accelerated solvent
828 extraction and laser irradiation that were used in ref. 43).

829

830

CONCLUSIONS

831 The results indicate that, due to the presence of active
832 substances which could alleviate the negative effects of diabetes,
833 the examined biowaste material from urban parks could be of
834 importance for the pharmaceutical industry in preparation of
835 high-value antidiabetic products. In general, ethanol in
836 concentration of 50 % was shown to be better suited than 10 %
837 ethanol for extraction of active principles of the selected plants
838 emphasizing the important role that the solvent selection plays

839 in the development of plant extracts-based products. Among the
840 tested extracts, those prepared from CI, MS, and TPr repeatedly
841 demonstrated superior antidiabetic potential due to their high
842 phenolic content, strong antioxidant, and anti-inflammatory
843 activity, as well as strong inhibition of α -glucosidase and α -
844 amylase. Future work should focus on pinpointing their active
845 principles, a task needed for potential preparation and
846 standardization of the antidiabetic medicines and/or food
847 supplements based on these plants.

848

849 *Acknowledgments.* – This research was funded by Croatian
850 Science Foundation, project Bioactive plant principles extraction
851 using green solvents – a step towards green cosmeceuticals,
852 grant number IP-2018-01-6504.

853

854 *Conflicts of interest.* – The authors declare no conflict of
855 interest.

856

857 *Authors contributions.* – Conceptualization, M.Z.K.;
858 methodology, M.M., L.J., L.V., M.J., M.Z.K.; validation, M.M.,
859 M.Z.K.; investigation, M.M., L.J., L.V. M.J., M.Z.K.; resources,
860 M.Z.K.; visualization, M.Z.K.; writing, original draft
861 preparation, M.Z.K.; writing, review and editing, M.M., L.J.,
862 L.V., M.J., M.Z.K.; supervision, M.Z.K.; project administration,
863 M.Z.K.; All authors have read and agreed to the published
864 version of the manuscript.

865

866 REFERENCES

867

868 REFERENCES

- 869 1. T. S. Han and M. E. Lean, A clinical perspective of obesity,
870 metabolic syndrome and cardiovascular disease, *JRSM*

- 871 *Cardiovasc. Dis.* **5** (2016) Article ID 2048004016633371
872 (13 pages); <https://doi.org/10.1177/2048004016633371>
- 873 2. T. V. Rohm, D. T. Meier, J. M. Olefsky and M. Y. Donath,
874 Inflammation in obesity, diabetes, and related disorders,
875 *Immunity* **55**(1) (2022) 31–55;
876 <https://doi.org/10.1016/j.immuni.2021.12.013>
- 877 3. T. V. Fiorentino, A. Prioleta, P. Zuo and F. Folli,
878 Hyperglycemia-induced oxidative stress and its role in
879 diabetes mellitus related cardiovascular diseases, *Curr.*
880 *Pharm. Des.* **19**(32) (2013) 5695–5703;
881 <https://doi.org/10.2174/1381612811319320005>
- 882 4. R. Kapoor and P. Kakkar, Protective role of morin, a
883 flavonoid, against high glucose induced oxidative stress
884 mediated apoptosis in primary rat hepatocytes, *PLoS One*
885 **7**(8) (2012) e41663 (11 pages);
886 <https://doi.org/10.1371/journal.pone.0041663>
- 887 5. D. Lin, M. Xiao, J. Zhao, Z. Li, B. Xing, X. Li, M. Kong, L.
888 Li, Q. Zhang, Y. Liu, H. Chen, W. Qin, H. Wu and S. Chen,
889 An overview of plant phenolic compounds and their
890 importance in human nutrition and management of type 2
891 diabetes, *Molecules* **21**(10) (2016) Article ID 1374 (19
892 pages); <https://doi.org/10.3390/molecules21101374>
- 893 6. C. G. Yedjou, J. Grigsby, A. Mbemi, D. Nelson, B. Mildort,
894 L. Latinwo and P. B. Tchounwou, The management of
895 diabetes mellitus using medicinal plants and vitamins, *Int.*
896 *J. Mol. Sci.* **24**(10) (2023) Article ID 9085 (14 pages);
897 <https://doi.org/10.3390/ijms24109085>

- 898 7. R. Naz, F. Saqib, S. Awadallah, M. Wahid, M. F. Latif, I.
899 Iqbal and M. S. Mubarak, Food polyphenols and type 2
900 diabetes mellitus: pharmacology and mechanisms,
901 *Molecules* **28**(10) (2023) Article ID 3996 (43 pages);
902 <https://doi.org/10.3390/molecules28103996>
- 903 8. B. Kukavica, S. Škondrić, T. Trifković, D. Mišić, U. Gašić,
904 L. Topalić-Trivunović, A. Savić, A. Velemir, B. Davidović-
905 Plavšić, M. Šešić and N. Lukić, Comparative polyphenolic
906 profiling of five ethnomedicinal plants and their applicative
907 potential in the treatment of type 2 diabetes, *J.*
908 *Ethnopharmacol.* **320** (2024) Article ID 117377 (14 pages);
909 <https://doi.org/10.1016/j.jep.2023.117377>
- 910 9. Y. Wen, L. He, R. Peng, Y. Lin, L. Zhao, X. Li, L. Ye and
911 J. Yang, A novel strategy to evaluate the quality of herbal
912 products based on the chemical profiling, efficacy
913 evaluation and pharmacokinetics, *J Pharm. Biomed. Anal.*
914 **161** (2018) 326–335;
915 <https://doi.org/10.1016/j.jpba.2018.08.047>
- 916 10. M. Feltynowski, J. Kronenberg, T. Bergier, N. Kabisch,
917 E. Łaszkiwicz and M. W. Strohbach, Challenges of urban
918 green space management in the face of using inadequate
919 data, *Urban For. Urban Gree.* **31** (2018) 56–66;
920 <https://doi.org/10.1016/j.ufug.2017.12.003>
- 921 11. R. Ravindran, S. S. Hassan, G. A. Williams and A. K.
922 Jaiswal, A review on bioconversion of agro-industrial
923 wastes to industrially important enzymes, *Bioengineering*
924 **5**(4) (2018) Article ID 93 (20 pages);
925 <https://doi.org/10.3390/bioengineering5040093>

- 926 12. A. Długoński and M. Szumański, Use of recreational park
927 bio-waste as locally available energy resource, *Ecol. Chem.*
928 *Eng. A* **23**(3) (2016) 2652–2674;
929 [https://doi.org/10.2428/ecea.2016.23\(3\)20](https://doi.org/10.2428/ecea.2016.23(3)20)
- 930 13. M. Marijan, J. Jablan, L. Jakupović, M. Jug, E. Marguí, R.
931 Dalipi, E. Sangiorgi and M. Zovko Končić, Plants from
932 urban parks as valuable cosmetic ingredients: green
933 extraction, chemical composition and activity, *Agronomy* **12**
934 (2022) Article ID 204 (14 pages);
935 <https://doi.org/10.3390/agronomy12010204>
- 936 14. V. L. Singleton, R. Orthofer and R. M. Lamuela-Raventós,
937 *Analysis of Total Phenols and Other Oxidation Substrates*
938 *and Antioxidants by Means of Folin-Ciocalteu Reagent*, in
939 *Methods in Enzymology* Vol. 299 (Ed. L. Packer), Elsevier,
940 Amsterdam 1999, pp. 152–178.
- 941 15. S. Kumazawa, T. Hamasaka and T. Nakayama, Antioxidant
942 activity of propolis of various geographic origins, *Food*
943 *Chem.* **84**(3) (2004) 329–339;
944 [https://doi.org/10.1016/S0308-8146\(03\)00216-4](https://doi.org/10.1016/S0308-8146(03)00216-4)
- 945 16. C. Nicolle, A. Carnat, D. Fraisse, J.-L. Lamaison, E. Rock,
946 H. Michel, P. Amouroux and C. Rémésy, Characterisation
947 and variation of antioxidant micronutrients in lettuce
948 (*Lactuca sativa* folium), *J. Sci. Food Agr.* **84**(15) (2004)
949 2061–2069; <https://doi.org/10.1002/jsfa.1916>
- 950 17. B. Fumić, M. Jug and M. Zovko Končić, Multi-response
951 optimization of ultrasound-assisted extraction of bioactive
952 components from *Medicago sativa* L., *Croat. Chem. Acta*
953 **90**(3) (2017) 481–491; <https://doi.org/10.5562/cca3228>

- 954 18.Z. Rajić, M. Zovko Končić, K. Miloloža, I. Perković, I.
955 Butula, F. Bucar and B. Zorc, Primaquine-NSAID twin
956 drugs: Synthesis, radical scavenging, antioxidant and Fe²⁺
957 chelating activity, *Acta Pharm.* **60**(3) (2010) 325–337;
958 <https://doi.org/10.2478/v10007-010-0024-9>
- 959 19. M. Zovko Končić, D. Kremer, K. Karlović and I. Kosalec,
960 Evaluation of antioxidant activities and phenolic content of
961 *Berberis vulgaris* L. and *Berberis croatica* Horvat, *Food*
962 *Chem. Toxicol.* **48**(8–9) (2010) 2176–2180;
963 <https://doi.org/10.1016/j.fct.2010.05.025>
- 964 20. K. M. Gillespie, J. M. Chae and E. A. Ainsworth, Rapid
965 measurement of total antioxidant capacity in plants, *Nat.*
966 *Protoc.* **2**(4) (2007) 867–870;
967 <https://doi.org/10.1038/nprot.2007.100>
- 968 21. S. Chekir, M. Debbabi, A. Regazzetti, D. Dargère, O.
969 Laprèvote, H. Ben Jannet and R. Gharbi, Design, synthesis
970 and biological evaluation of novel 1,2,3-triazole linked
971 coumarinopyrazole conjugates as potent anticholinesterase,
972 anti-5-lipoxygenase, anti-tyrosinase and anticancer agents,
973 *Bioorg. Chem.* **80** (2018) 189–194;
974 <https://doi.org/10.1016/j.bioorg.2018.06.005>
- 975 22. S. Chandra, P. Chatterjee, P. Dey and S. Bhattacharya,
976 Evaluation of in vitro anti-inflammatory activity of coffee
977 against the denaturation of protein, *Asian Pac. J. Trop.*
978 *Biomed.* **2**(1) (2012) S178–S180;
979 [https://doi.org/10.1016/S2221-1691\(12\)60154-3](https://doi.org/10.1016/S2221-1691(12)60154-3)
- 980 23. Y. Zhang, Y. Fu, S. Zhou, L. Kang and C. Li, A
981 straightforward ninhydrin-based method for collagenase

- 982 activity and inhibitor screening of collagenase using
983 spectrophotometry, *Anal. Biochem.* **437**(1) (2013) 46–48;
984 <https://doi.org/10.1016/j.ab.2013.02.030>
- 985 24. E. Apostolidis, Y.-I. Kwon and K. Shetty, Inhibitory
986 potential of herb, fruit, and fungal-enriched cheese against
987 key enzymes linked to type 2 diabetes and hypertension,
988 *Innov. Food Sci. Emerg.* **8**(1) (2007) 46–54;
989 <https://doi.org/10.1016/j.ifset.2006.06.001>
- 990 25. K. Bljajić, R. Petlevski, L. Vujić, A. Čačić, N. Šošarić, J.
991 Jablan, I. Saraiva de Carvalho and M. Zovko Končić,
992 Chemical composition, antioxidant and α -glucosidase-
993 inhibiting activities of the aqueous and hydroethanolic
994 extracts of *Vaccinium myrtillus* leaves, *Molecules* **22**(5)
995 (2017) Article ID 703 (14 pages);
996 <https://doi.org/10.3390/molecules22050703>
- 997 26. M. Zovko Končić and K. Bljajić, *Traditional Herbal*
998 *Products Used for the Management of Diabetes in Croatia:*
999 *Linking Traditional Use with α -Glucosidase-Inhibitory*
1000 *Activity*, in *Bioactive Food as Dietary Interventions for*
1001 *Diabetes* (Eds. R. R. Watson & V. R. Preedy), 2nd ed.
1002 Academic Press, Cambridge, Massachusetts 2019, pp. 647–
1003 664.
- 1004 27. S. K. Swanston-Flatt, C. Day, C. J. Bailey and P. R. Flatt,
1005 Traditional plant treatments for diabetes. Studies in normal
1006 and streptozotocin diabetic mice, *Diabetologia* **33**(8) (1990)
1007 462–464; <https://doi.org/10.1007/BF00405106>
- 1008 28. E. P. Verhulst, N. P. Brunton and D. K. Rai, Polyphenols in
1009 agricultural grassland crops and their health-promoting

- 1010 activities – A review, *Foods* **12**(22) (2023) Article ID 4122
1011 (19 pages); <https://doi.org/10.3390/foods12224122>
- 1012 29. R. Vinayagam, M. Jayachandran and B. Xu, Antidiabetic
1013 effects of simple phenolic acids: A comprehensive review,
1014 *Phytother. Res.* **30**(2) (2016) 184–199;
1015 <https://doi.org/10.1002/ptr.5528>
- 1016 30. Z. Chen, S. Zheng, L. Li and H. Jiang, Metabolism of
1017 flavonoids in human: A comprehensive review, *Curr. Drug*
1018 *Metab.* **15**(1) (2014) 48–61;
1019 <https://doi.org/10.2174/138920021501140218125020>
- 1020 31. K. Bljajić, A. Brajković, A. Čačić, L. Vujić, J. Jablan, I.
1021 Saraiva de Carvalho and M. Zovko Končić, Chemical
1022 composition, antioxidant, and α -glucosidase-inhibiting
1023 activity of aqueous and hydroethanolic extracts of
1024 traditional antidiabetics from Croatian ethnomedicine,
1025 *Horticulturae* **7**(2) (2021) Article ID 15 (19 pages);
1026 <https://doi.org/10.3390/horticulturae7020015>
- 1027 32. T.-W. Hung, M.-Y. Yang, M.-H. Yu, I.-N. Tsai, Y.-C. Tsai,
1028 K.-C. Chan and C.-J. Wang, Mulberry leaf extract and
1029 neochlorogenic acid ameliorate glucolipotoxicity-induced
1030 diabetic nephropathy in high-fat diet-fed db/db mice, *Food*
1031 *Funct.* **14**(19) (2023) 8975–8986;
1032 <https://doi.org/10.1039/d3fo02640j>
- 1033 33. K. Alipieva, L. Korkina, I. E. Orhan and M. I. Georgiev,
1034 Verbascoside – A review of its occurrence, (bio)synthesis
1035 and pharmacological significance, *Biotechnol. Adv.* **32**(6)
1036 (2014) 1065–1076;
1037 <https://doi.org/10.1016/j.biotechadv.2014.07.001>

- 1038 34. Y. Xiao, Q. Ren and L. Wu, The pharmacokinetic property
1039 and pharmacological activity of acteoside: A review,
1040 *Biomed. Pharmacother.* **153** (2022) Article ID 113296 (13
1041 pages); <https://doi.org/10.1016/j.biopha.2022.113296>
- 1042 35. B. Salehi, A. Venditti, M. Sharifi-Rad, D. Kręgiel, J. Sharifi-
1043 Rad, A. Durazzo, M. Lucarini, A. Santini, E. B. Souto, E.
1044 Novellino, H. Antolak, E. Azzini, W. N. Setzer and N.
1045 Martins, The therapeutic potential of apigenin, *Int. J. Mol.*
1046 *Sci.* **20**(6) (2019) Article ID 1305 (26 pages);
1047 <https://doi.org/10.3390/ijms20061305>
- 1048 36. Z. Wang, M. Zeng, Z. Wang, F. Qin, J. Chen and Z. He,
1049 Dietary luteolin: A narrative review focusing on its
1050 pharmacokinetic properties and effects on glycolipid
1051 metabolism, *J. Agric. Food. Chem.* **69**(5) (2021) 1441–
1052 1454; <https://doi.org/10.1021/acs.jafc.0c08085>
- 1053 37. L. Moldovan, A. Gaspar, L. Toma, O. Craciunescu and C.
1054 Saviuc, Comparison of polyphenolic content and
1055 antioxidant capacity of five Romanian traditional medicinal
1056 plants, *Rev. Chim.-Bucharest* **62**(3) (2011) 299–303;
1057 <https://doi.org/10.37358/Rev.Chim.1949>
- 1058 38. S. Delfine, M. Marrelli, F. Conforti, C. Formisano, D.
1059 Rigano, F. Menichini and F. Senatore, Variation of *Malva*
1060 *sylvestris* essential oil yield, chemical composition and
1061 biological activity in response to different environments
1062 across Southern Italy, *Ind. Crop Prod.* **98** (2017) 29–37;
1063 <https://doi.org/10.1016/j.indcrop.2017.01.016>
- 1064 39. R. Chawla, P. Thakur, A. Chowdhry, S. Jaiswal, A. Sharma,
1065 R. Goel, J. Sharma, S. S. Priyadarshi, V. Kumar, R. K.

- 1066 Sharma and R. Arora, Evidence based herbal drug
1067 standardization approach in coping with challenges of
1068 holistic management of diabetes: A dreadful lifestyle
1069 disorder of 21st century, *J. Diabetes Metab. Disord.* **12**(1)
1070 (2013) Article ID 35 (16 pages);
1071 <https://doi.org/10.1186/2251-6581-12-35>
- 1072 40. A. Helmstädter, Beans and diabetes: *Phaseolus vulgaris*
1073 preparations as antihyperglycemic agents, *J. Med. Food.*
1074 **13**(2) (2010) 251–254;
1075 <https://doi.org/10.1089/jmf.2009.0002>
- 1076 41. I. Faraone, D. K. Rai, D. Russo, L. Chiumminto, E.
1077 Fernandez, A. Choudhary and L. Milella, Antioxidant,
1078 antidiabetic, and anticholinesterase activities and
1079 phytochemical profile of *Azorella glabra* Wedd, *Plants* **8**(8)
1080 (2019) Article ID 265 (14 pages);
1081 <https://doi.org/10.3390/plants8080265>
- 1082 42. P. Van Hung, Phenolic compounds of cereals and their
1083 antioxidant capacity, *Crit. Rev. Food Sci. Nutr.* **56**(1) (2016)
1084 25–35; <https://doi.org/10.1080/10408398.2012.708909>
- 1085 43. G. Paun, E. Neagu, A. Alecu, C. Albu, A.-M. Seciu-Grama
1086 and G. L. Radu, Evaluating the antioxidant and antidiabetic
1087 properties of *Medicago sativa* and *Solidago virgaurea*
1088 polyphenolic-rich extracts, *Molecules* **29**(2) (2024) Article
1089 ID 326 (13 pages);
1090 <https://doi.org/10.3390/molecules29020326>
- 1091 44. V. Aruna, G. V. Amruthavalli and R. Gayathri, Use of
1092 cosmetic products for treating certain diseases—Know the

- 1093 science, *J. Cosmet. Dermatol.* **18**(1) (2019) 221–225;
1094 <https://doi.org/10.1111/jocd.12544>
- 1095 45. H. Kuhn, Biologic relevance of lipoxygenase isoforms in
1096 atherogenesis, *Expert. Rev. Cardiovasc. Ther.* **3**(6) (2005)
1097 1099–1110; <https://doi.org/10.1586/14779072.3.6.1099>
- 1098 46. M. Abas, M. El Masry and H. Elgharably, *Collagen in*
1099 *Diabetic Wound Healing*, in *Wound Healing, Tissue Repair,*
1100 *and Regeneration in Diabetes* (Eds. D. Bagchi, A. Das, &
1101 S. Roy), Academic Press, Cambridge, Massachusetts 2020,
1102 pp. 393–401.
- 1103 47. U. Gawlik-Dziki and M. Świeca, Sprouts of selected plants
1104 as a source of bioavailable antioxidants and lipoxygenase
1105 inhibitors, *Annales Universitatis Mariae Curie-Sklodowska,*
1106 *Sectio DDD: Pharmacia* **24**(3) (2011) 161–168.
- 1107 48. N. Matvieieva, V. Bessarabov, O. Khainakova, V. Duplij,
1108 T. Bohdanovych, Y. Ratushnyak, G. Kuzmina, V. Lisovyi,
1109 N. Zderko and N. Kobylinska, *Cichorium intybus* L. “hairy”
1110 roots as a rich source of antioxidants and anti-inflammatory
1111 compounds, *Heliyon* **9**(3) (2023) e14516 (13 pages);
1112 <https://doi.org/10.1016/j.heliyon.2023.e14516>
- 1113 49. T. S. A. Thring, P. Hili and D. P. Naughton, Anti-
1114 collagenase, anti-elastase and anti-oxidant activities of
1115 extracts from 21 plants, *BMC Complem. Altern. M.* **9** (2009)
1116 Article ID 27 (11 pages); [https://doi.org/10.1186/1472-](https://doi.org/10.1186/1472-6882-9-27)
1117 [6882-9-27](https://doi.org/10.1186/1472-6882-9-27)
- 1118 50. I. Süntar, E. Küpeli Akkol, H. Keles, E. Yesilada, S. D.
1119 Sarker and T. Baykal, Comparative evaluation of traditional
1120 prescriptions from *Cichorium intybus* L. for wound healing:

- 1121 Stepwise isolation of an active component by *in vivo*
1122 bioassay and its mode of activity, *J. Ethnopharmacol.*
1123 **143**(1) (2012) 299–309;
1124 <https://doi.org/10.1016/j.jep.2012.06.036>
- 1125 51. A. Z. Alsarayreh, S. A. Oran, J. M. Shakhanbeh, K. M.
1126 Khleifat, Y. T. Al Qaisi, I. I. Alfarrayeh and A. M.
1127 Alkaramseh, Efficacy of methanolic extracts of some
1128 medicinal plants on wound healing in diabetic rats, *Heliyon*
1129 **8**(8) (2022) e10071 (9 pages);
1130 <https://doi.org/10.1016/j.heliyon.2022.e10071>
- 1131 52. J. Truba, I. Stanisławska, M. Walasek, W. Wieczorkowska,
1132 K. Woliński, T. Buchholz, M. F. Melzig and M. E.
1133 Czerwińska, Inhibition of digestive enzymes and
1134 antioxidant activity of extracts from fruits of *Cornus alba*,
1135 *Cornus sanguinea subsp. hungarica* and *Cornus florida* – A
1136 comparative study, *Plants* **9**(1) (2020) Article ID 122 (15
1137 pages); <https://doi.org/10.3390/plants9010122>
- 1138 53. M. Hawash, N. Jaradat, J. Elaraj, A. Hamdan, S. A. Lebdeh
1139 and T. Halawa, Evaluation of the hypoglycemic effect of
1140 seven wild folkloric edible plants from Palestine, *J.*
1141 *Complement. Integr. Med.* **17**(1) (2020) Article ID
1142 20190032 (10 pages); [https://doi.org/10.1515/jcim-2019-](https://doi.org/10.1515/jcim-2019-0032)
1143 0032